Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE reschedules DES coverage meeting

This article was originally published in The Gray Sheet

Executive Summary

UK's National Institute of Health and Clinical Excellence (NICE) appraisal committee meeting to consider whether to move forward with preliminary recommendations that the National Health Service of England and Wales stop paying for drug-eluting stents, originally scheduled for Sept. 4, is rescheduled to Nov. 6 to allow conferees time to consider information from recently available economic models. The medical community in Britain is strongly opposing NICE's preliminary appraisal, making it more likely that the final policy will be toned down (1"The Gray Sheet" Sept. 3, 2007, p. 3)...

You may also be interested in...



Preliminary Recs Would Stop Payments For Drug-Eluting Stents In Britain

A committee meets this week to consider whether to move forward with preliminary recommendations for the Nation Health Service of England and Wales to stop paying for drug-eluting stents

E.l.f. Has A Go At Twitch Crowd, Hitching Wagon To #Loserfruit

The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.

An Oversupply Of COVID Antibody Treatments? Multiple Monoclonal Products Raise Potential For Errors

As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel